DK0731787T3 - Krystallinsk, polymorf form af (S,S,S)-N-(1-[2-carboxy-3-(N2-mesyllysylamino)-propyl]-1-cyclopentylcarbonyl)-tyrosin - Google Patents

Krystallinsk, polymorf form af (S,S,S)-N-(1-[2-carboxy-3-(N2-mesyllysylamino)-propyl]-1-cyclopentylcarbonyl)-tyrosin

Info

Publication number
DK0731787T3
DK0731787T3 DK95900719T DK95900719T DK0731787T3 DK 0731787 T3 DK0731787 T3 DK 0731787T3 DK 95900719 T DK95900719 T DK 95900719T DK 95900719 T DK95900719 T DK 95900719T DK 0731787 T3 DK0731787 T3 DK 0731787T3
Authority
DK
Denmark
Prior art keywords
polymorphic form
crystalline
mesyllysylamino
cyclopentylcarbonyl
tyrosine
Prior art date
Application number
DK95900719T
Other languages
Danish (da)
English (en)
Inventor
Peter James Dunn
Michael Leslie Hughes
Original Assignee
Pfizer Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Res & Dev filed Critical Pfizer Res & Dev
Application granted granted Critical
Publication of DK0731787T3 publication Critical patent/DK0731787T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrrole Compounds (AREA)
DK95900719T 1993-12-04 1994-11-09 Krystallinsk, polymorf form af (S,S,S)-N-(1-[2-carboxy-3-(N2-mesyllysylamino)-propyl]-1-cyclopentylcarbonyl)-tyrosin DK0731787T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939324931A GB9324931D0 (en) 1993-12-04 1993-12-04 Glutaramide derivatives
PCT/EP1994/003750 WO1995015308A1 (en) 1993-12-04 1994-11-09 Crystalline, polymorphic form of (s,s,s)-n-(1-[2-carboxy-3-(n2-mesyllysylamino)propyl]-1-cyclopentylcarbonyl)tyrosine

Publications (1)

Publication Number Publication Date
DK0731787T3 true DK0731787T3 (da) 1999-08-30

Family

ID=10746163

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95900719T DK0731787T3 (da) 1993-12-04 1994-11-09 Krystallinsk, polymorf form af (S,S,S)-N-(1-[2-carboxy-3-(N2-mesyllysylamino)-propyl]-1-cyclopentylcarbonyl)-tyrosin

Country Status (26)

Country Link
US (1) US6180665B1 (sv)
EP (1) EP0731787B1 (sv)
JP (1) JP2701988B2 (sv)
KR (1) KR100203314B1 (sv)
CN (1) CN1068586C (sv)
AT (1) ATE175664T1 (sv)
CA (1) CA2178085C (sv)
CZ (1) CZ296428B6 (sv)
DE (1) DE69416003T2 (sv)
DK (1) DK0731787T3 (sv)
EG (1) EG20562A (sv)
ES (1) ES2128031T3 (sv)
FI (1) FI120305B (sv)
GB (1) GB9324931D0 (sv)
GR (1) GR3029590T3 (sv)
HU (1) HU225959B1 (sv)
IL (1) IL111791A (sv)
MY (1) MY115430A (sv)
NO (1) NO306714B1 (sv)
NZ (1) NZ276087A (sv)
PE (1) PE9296A1 (sv)
PL (1) PL178559B1 (sv)
RU (1) RU2131869C1 (sv)
TW (2) TW434210B (sv)
WO (1) WO1995015308A1 (sv)
ZA (1) ZA949595B (sv)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7004344B2 (en) 2000-08-29 2006-02-28 Tolko Industries Ltd. Collapsible bin
FR2824477B1 (fr) * 2001-05-09 2005-09-09 Ethypharm Lab Prod Ethiques Granules enrobes a base d'inhibiteur de l'enzyme de conversion de l'anfiotensine, leur procede de preparation et comprimes orodispersibles contenant les granules enrobes
US6975515B2 (en) 2001-08-15 2005-12-13 Agilent Technologies, Inc. Electrical module
CN102285916B (zh) * 2003-02-12 2015-02-25 日产化学工业株式会社 匹伐他汀钙的晶形
WO2005123702A1 (en) * 2004-06-15 2005-12-29 Pfizer Limited Neutral endopeptidase inhibitor polymorph
CN109350736A (zh) * 2018-09-20 2019-02-19 南通大学 防治运动病、梅尼埃病的药物及心房钠尿肽的医药用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8820844D0 (en) 1988-09-05 1988-10-05 Pfizer Ltd Therapeutic agents
US5208236A (en) * 1992-09-23 1993-05-04 Schering Corporation N-(acylaminomethyl)glutaryl amino acids and use

Also Published As

Publication number Publication date
GR3029590T3 (en) 1999-06-30
KR960706470A (ko) 1996-12-09
WO1995015308A1 (en) 1995-06-08
TW534901B (en) 2003-06-01
TW434210B (en) 2001-05-16
EP0731787A1 (en) 1996-09-18
EP0731787B1 (en) 1999-01-13
IL111791A (en) 2002-09-12
HU9601506D0 (en) 1996-07-29
CZ296428B6 (cs) 2006-03-15
PE9296A1 (es) 1996-04-04
HU225959B1 (en) 2008-01-28
MY115430A (en) 2003-06-30
NO962294D0 (no) 1996-06-04
FI962322A0 (sv) 1996-06-03
CZ160496A3 (en) 1996-11-13
EG20562A (en) 1999-08-30
AU684114B2 (en) 1997-12-04
JPH09500654A (ja) 1997-01-21
NZ276087A (en) 1997-11-24
PL314794A1 (en) 1996-09-30
JP2701988B2 (ja) 1998-01-21
CN1068586C (zh) 2001-07-18
GB9324931D0 (en) 1994-01-26
AU8142494A (en) 1995-06-19
ATE175664T1 (de) 1999-01-15
CA2178085C (en) 2002-09-03
CA2178085A1 (en) 1995-06-08
ZA949595B (en) 1996-06-03
FI962322A (sv) 1996-06-03
FI120305B (sv) 2009-09-15
PL178559B1 (pl) 2000-05-31
CN1142816A (zh) 1997-02-12
IL111791A0 (en) 1995-01-24
DE69416003D1 (en) 1999-02-25
NO962294L (no) 1996-06-04
US6180665B1 (en) 2001-01-30
ES2128031T3 (es) 1999-05-01
HUT74683A (en) 1997-01-28
DE69416003T2 (de) 1999-05-27
NO306714B1 (no) 1999-12-13
RU2131869C1 (ru) 1999-06-20
KR100203314B1 (ko) 1999-06-15

Similar Documents

Publication Publication Date Title
YU34896A (sh) Supstituisani n-(indol-2-karbonil)-glicinamidi, njihovi intermedijeri i farmaceutske kompozicije
NO955047L (no) Sekundære aminer som antidiabetiske og antifedme-midler
DE69729583D1 (de) N-(amidinophenyl)-n'-(subst.)-3h-2,4-benzodiazepin-3-on derivative als faktor xa inhibitoren
BR9806296B1 (pt) compostos de ácido sulfìnico, mistura, composição e uso dos mesmos.
DK0595851T3 (da) Fremgangsmåde til fremstilling af sertralin-mellemprodukter
NO961377L (no) Distamycin A-analoger som antitumor eller antivirale midler
ATE206402T1 (de) 3-acylaminobenzazepine
DK0619806T3 (da) Fremstilling af substituerede piperidiner
NZ331875A (en) Asymmetric synthesis of R-alpha-propyl-piperonyl amine and its analogs
DK0731787T3 (da) Krystallinsk, polymorf form af (S,S,S)-N-(1-[2-carboxy-3-(N2-mesyllysylamino)-propyl]-1-cyclopentylcarbonyl)-tyrosin
BR9807988A (pt) Processo para a preparação de um composto, e, composto.
DK0745081T3 (da) Indan-2-mercaptoacetylamiddisulfidderivater, der er anvendelige som enkephalinase-inhibitorer
PL343546A1 (en) Processes for preparing intermediates
DK1347960T3 (da) Fremgangsmåde til fremstilling af (+/-) trans-4-p-fluorphenyl-3-hydromethyl-1-methylpiperidin
BR0010488A (pt) Tienocicloalqu(en)ilamino-1,3,5-triazinas substituìdas
DK0613896T3 (da) Fremgangsmåde til fremstilling af sulfonylurinstofderivater
DK1320527T3 (da) Fremgangsmåde til fremstilling af 1-substituerede 5-chlor-4-methylpytrazoler
DE50206142D1 (de) Verfahren zur herstellung von 1,3-disubstituierten 2-nitroguanidinen
DK1572615T3 (da) Fremgangsmåde til syntese af peptider indeholdende en 4-hydroxyprolin-substruktur
ATE244217T1 (de) Herstellung von beta-mehtylcarbapenem- zwischenprodukten